Clinical Trials Logo

Chemotherapy clinical trials

View clinical trials related to Chemotherapy.

Filter by:

NCT ID: NCT03868865 Completed - Breast Cancer Clinical Trials

Effects of an Integrative Day-care Clinic Program for Breast Cancer Patients During Chemotherapy

Start date: August 7, 2012
Phase: N/A
Study type: Interventional

The aim of the study was to evaluate a new integrative day-care clinic concept for breast cancer patients receiving chemotherapy. This is an explorative pilot study. Therefore, all outcomes are analyzed exploratively.

NCT ID: NCT03863912 Completed - Quality of Life Clinical Trials

Impact of Disney Movies During Chemotherapy on QOL of Gynecologic Oncology Patients

Start date: December 1, 2017
Phase: N/A
Study type: Interventional

To evaluate the impact of Disney movies on quality of life (QOL) of gynecologic oncology patients. 25 Patients are watching Disney movies on portable DVD players during chemotherapy, 25 patients are not allowed to watch TV. EORTC QLQ-C30 and EORTC QLQ-FA12 surveys are given to the patients before and after the six chemotherapies. Hypothesis: Disney movies can elevate patients QOL.

NCT ID: NCT03862144 Completed - Clinical trials for Chemotherapy-induced Nausea and Vomiting

NEPA to Prevent Chemotherapy Induced Nausea and Vomiting in Patients With Breast Cancer

GIM15-NEPA
Start date: May 12, 2016
Phase: Phase 2
Study type: Interventional

This study evaluates if the activity of one-day of NEPA plus dexamethasone, to prevent chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant AC-based chemotherapy, is maintained during all the chemotherapy cycle treatment (maximum 4 cycles).

NCT ID: NCT03854864 Completed - Clinical trials for Chemotherapy-induced Peripheral Neuropathy

Evaluation by Oncologists of Strategies for the Prevention and Treatment of Chemotherapy-induced Peripheral Neuropathies

EVANEURO
Start date: January 14, 2019
Phase:
Study type: Observational

Chemotherapy induced peripheral neuropathy (CIPN) is one of the most deleterious adverse effect of neurotoxic anticancer drugs affecting up to 40% of patients. These neurotoxic anticancer agents include mainly: cisplatin (bronchopulmonary cancers), oxaliplatin (colorectal cancers), paclitaxel (breast cancers and bronchopulmonary cancers), docetaxel (breast cancers and bronchopulmonary cancers) and bortezomib (multiple myeloma). CIPN affects not only the quality of life of patients, it also has a major impact on oncology strategy, forcing oncologists to reduce dose-intensity, to stop an ongoing chemotherapy regimen and to change therapeutic strategies, with a risk of compromising patients' survival. There is no real preventive or curative treatment (except duloxetine) for CIPN and it is not known what is the practice of oncologists in France? However, it is essential to know the degree of sensitivity of oncologists to this problem and their practice. With this study, the investigators propose to assess the current practices of management by oncologists in France in 2019, for any type of practitioners of university hospital, or general hospital, for all type of neurotoxic anticancer drugs.

NCT ID: NCT03824860 Completed - Chronic Pain Clinical Trials

Yoga for Painful Chemotherapy-Induced Peripheral Neuropathy: A Pilot, Randomized-Controlled Study

Start date: August 6, 2019
Phase: N/A
Study type: Interventional

This research study will examine the feasibility of conducting an eight-week yoga intervention for individuals with chronic painful chemotherapy-induced peripheral neuropathy.

NCT ID: NCT03816904 Completed - Breast Cancer Clinical Trials

Involvement of SK3 Calcium Channel in Taxane Neuropathy

NEUROTAX
Start date: February 6, 2019
Phase:
Study type: Observational

Taxane neuropathy is a common and long-term side effect of long-term morbidity in patients surviving cancer. No preventive or symptomatic treatment has been shown to be effective. Its pathophysiology is poorly known and probably multifactorial. A possible mechanism would be mediated by the activation of the SK3 calcium channel: a retrospective study carried out at the University Hospital of Tours (Carina RUA) found a significant association between the number of CAG triplets in the KCNN3 gene coding for the SK3 channel and the appearance of a taxane neuropathy.

NCT ID: NCT03798379 Completed - Clinical trials for Chemotherapy-induced Peripheral Neuropathy

Exercises for Patients Who Were Receiving Chemotherapy

Start date: October 1, 2015
Phase: N/A
Study type: Interventional

To evaluate the effect of lower extremity strengthening and balance exercises on balance, quality of life and neuropathic pain of the cancer patients receiving neurotoxic chemotherapy.

NCT ID: NCT03786055 Completed - Pain Clinical Trials

Somatic Yoga and Meditation for Cancer Survivors With Pain From Neuropathy

Y4CIPN
Start date: June 4, 2018
Phase: N/A
Study type: Interventional

Chemotherapy-induced peripheral neuropathy syndrome (CIPN) causes significant pain in hands and feet and is an adverse effect of treatment. Few non-pharmacological interventions have been tested and individuals experience CIPN symptoms years after treatment. This is the first study to explore a somatic yoga and meditation (SYM) intervention on functional outcomes and quality of life in cancer survivors.

NCT ID: NCT03764514 Completed - Clinical trials for Chemotherapy-induced Peripheral Neuropathy

Spinal Cord Stimulation in Chemotherapy Induced Neuropathy

Start date: December 3, 2018
Phase:
Study type: Observational

This is an observational based pilot study evaluating the use of spinal cord stimulators for the treatment of chemotherapy induced peripheral neuropathy will lead to an increase in quality of life and decrease in pain.

NCT ID: NCT03762694 Completed - Clinical trials for Breast Cancer Female

The Effect of Acupuncture for Insomnia in Breast Cancer Patients Undergoing Chemotherapy

Start date: March 26, 2019
Phase: N/A
Study type: Interventional

This pilot study is designed to determine whether acupuncture is a feasible, effective and safe method for alleviating insomnia among breast cancer patients undergoing chemotherapy as compared with a wait-list control.